A 72.2% confirmed objective response rate in first-line RAS-mutated metastatic colorectal cancer — against 43.2% across combined standard-of-care arms — is the number Cardiff Oncology carried into its End-of-Phase 2 FDA meeting, and the agency apparently found it compelling enough to align on a Phase 3 design. That hazard ratio of 0.38 for progression-free survival versus FOLFIRI/bevacizumab is not a marginal signal. It is the kind of separation that, if it replicates in a registrational trial, rewrites the front-line RAS-mutated mCRC algorithm entirely.
The FDA meeting produced two concrete decisions: 30 mg onvansertib is the selected dose, and FOLFIRI/bev is the chosen chemotherapy backbone. The FOLFOX arm is out. That choice matters clinically — FOLFIRI/bev was the arm that generated the dramatic PFS separation in Phase 2, while FOLFOX combinations did not produce the same magnitude of benefit, suggesting the pharmacological interaction between PLK1 inhibition and irinotecan-based therapy is mechanistically specific, not a class effect of any doublet. Cardiff has not disclosed whether the Phase 3 primary endpoint will be PFS or overall survival, a detail that will define the trial’s risk profile and timeline substantially.
The financial picture adds urgency to execution. Cardiff has $46.1 million in cash and burns roughly $12.3 million per quarter in operating activities, giving it a runway into Q1 2027 by its own projection. A Phase 3 trial in mCRC — enrollment, site activation, and data maturation — costs far more than that. The company is running toward a capital raise or partnership before the Phase 3 engine fully ignites, and the ASCO rapid oral presentation on May 29 is the clearest opportunity to strengthen that negotiating position. Updated CRDF-004 data in front of the oncology community, carrying mature PFS curves and response depth metrics, will either validate the Phase 2 signal or expose fragility in it.
The single marker to track at ASCO is whether the updated data shows deepening responses over time — specifically whether complete response rates are emerging in the FOLFIRI/bev arm — because durable CRs in RAS-mutated mCRC would be genuinely unprecedented and would lock in the scientific case for a large, expensive Phase 3 before the cash clock runs out.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
